Journal article
ISTH guidelines for antithrombotic treatment in COVID‐19
Abstract
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants …
Authors
Schulman S; Sholzberg M; Spyropoulos AC; Zarychanski R; Resnick HE; Bradbury CA; Connors JM; Falanga A; Iba T; Kaatz S
Journal
Journal of Thrombosis and Haemostasis, Vol. 20, No. 10, pp. 2214–2225
Publisher
Elsevier
Publication Date
October 2022
DOI
10.1111/jth.15808
ISSN
1538-7933